Liver Metastasis Colon Cancer Clinical Trial
Official title:
A Phase II Study of Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Fruquintinib as Third-line Therapy for Patients With Unresectable Colorectal Cancer Liver Metastases
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. Combined with hepatic arterial infusion chemotherapy (HAIC), this study is conducted to assess the efficacy and safety of this regimen in patients with unresectable colorectal cancer liver metastases as the third-line therapy.
This will be a single-arm, open-label, phase II study. This study will be divided into 2 stages: dose exploration and dose expansion. In the dose exploration stage, "3+3 dose escalation" design will be applied to determined the maximum tolerated dose (MTD) of fruquintinib for next stage: Cohort A: HAIC + fruquintinib 3mg QD, 3 weeks on/1 week off (3w/1w). Cohort B: HAIC + fruquintinib 4mg QD, 3w/1w. Cohort C: HAIC + fruquintinib 5mg QD, 3w/1w. All subjects of this study will be permitted to continue therapy with only safety monitoring and assessments for progression, if the product is well tolerated and the subject has stable disease or better. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03562234 -
The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases
|
||
| Recruiting |
NCT03732235 -
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
|
||
| Recruiting |
NCT06126419 -
Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
|
N/A | |
| Active, not recruiting |
NCT05616039 -
I-FIGS Feasibility Study
|
N/A | |
| Withdrawn |
NCT05175092 -
Living Donor Liver Transplantation for CRC Liver Metastases
|
N/A | |
| Recruiting |
NCT04798898 -
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
|
N/A | |
| Not yet recruiting |
NCT06071052 -
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
|
N/A | |
| Not yet recruiting |
NCT06053996 -
Hepatopulmonary Radio-sterilization With Immunotherapy
|
N/A | |
| Recruiting |
NCT04491929 -
Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
|
||
| Not yet recruiting |
NCT06050200 -
TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery
|
N/A | |
| Enrolling by invitation |
NCT03444194 -
Treatment Response Evaluation in Patients With Non-resectable Colorectal Liver Metastases A Feasibility Study
|
N/A | |
| Not yet recruiting |
NCT05884723 -
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
|
N/A | |
| Not yet recruiting |
NCT06185556 -
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05755672 -
On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
|
||
| Recruiting |
NCT04595266 -
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
|
Phase 2 | |
| Recruiting |
NCT04701281 -
Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05775146 -
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
|
Phase 2 | |
| Recruiting |
NCT06200831 -
Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
|
N/A | |
| Active, not recruiting |
NCT04046445 -
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
|
Phase 1 |